STAAR CFO to Retire in 2020
December 18 2019 - 4:05PM
Business Wire
Deborah Andrews Plans to Retire After 24
Years with the Company
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of implantable lenses and companion
delivery systems for the eye, today announced that following a
successful 24-year career with the Company, Deborah Andrews plans
to retire from the company in 2020. Andrews will continue in her
role as Chief Financial Officer until her successor is appointed,
and then remain with the company during a transition period until
her retirement.
"On behalf of everyone at STAAR, I thank Deborah for her
dedication and contributions during her more than two-decade career
at STAAR," said Caren Mason, President and CEO. "STAAR has a strong
finance team and Deborah has played an important role in helping
implement financial and operational improvements as we work to
enhance our position as the global premium solution for patients
seeking visual freedom from spectacles and contact lenses. I am
appreciative that Deborah will remain with STAAR to help facilitate
a smooth leadership transition and wish her all the best in her
retirement."
"It has been a privilege to work alongside the talented and
dedicated STAAR team," said Andrews. "I am proud of the progress we
have made and the team we have built. I remain confident in the
future promise of STAAR and am committed to ensuring a smooth
transition."
STAAR is conducting an external search for its next CFO.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 30 years, designs, develops, manufactures and markets
implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients,
lessening or eliminating the reliance on glasses or contact lenses.
All of these lenses are foldable, which permits the surgeon to
insert them through a small incision. STAAR’s lens used in
refractive surgery is called an Implantable Collamer® Lens or
“ICL”, which includes the EVO Visian ICL™ product line. More than
1,000,000 Visian® ICLs have been implanted to date and STAAR
markets these lenses in over 75 countries. To learn more about the
ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191218005714/en/
Investors & Media Brian Moore Sr. Director, Investor,
Media Relations and Corporate Development (626) 303-7902, Ext. 3023
bmoore@staar.com
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Jun 2024 to Jul 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Jul 2023 to Jul 2024